Načítá se...
Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
OBJECTIVE: To compare the cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in patients with atrial fibrillation (AF). METHODS: Using standard methods, we created a Markov decision model based on the estimated cost of apixaban and data from the Apixaban for Reduction in Stro...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Lippincott Williams & Wilkins
2012
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3525294/ https://ncbi.nlm.nih.gov/pubmed/22993279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e31826d5fe8 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|